Tempus AI, Inc. bought $2.6M of Personalis (PSNL)
Executed Nov 18 2025, disclosed Feb 13, 87 days later, against a two-business-day limit.
Over the 21 trading sessions from the disclosed entry session (Feb 13), the stock returned -19.6% (delay-adjusted); from the execution session (Nov 18 2025), +5.0%. Derived: entry at the session's open, exit at the close 20 sessions later.
Tempus AI, Inc. (10% owner) filed 1 Form 4 report as a reporting entity in the trailing twelve months (1 purchase, 0 sales, 1 filed past the two-business-day deadline), most often in Personalis, Inc. (PSNL). Across 1 priced purchase filing, the average 21-session return was +5.0% from execution and -19.6% from disclosure (delay-adjusted; derived). The largest single filing was $2.6M of PSNL (300,655 sh across 10 lots, as filed), executed Nov 18 2025.
Healthcare · Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→